management of sarcomas october 25, 2014 missoula, montana soft tissue sarcomas: a multi-disciplinary...
TRANSCRIPT
Management of Sarcomas
October 25, 2014Missoula, Montana
Soft Tissue Sarcomas:
A Multi-Disciplinary Strategy of Care
Darin J. Davidson, MD, MHSc, FRCSCDepartment of Orthopaedics and Sports Medicine
Assistant Professor, University of Washington School of MedicineOrthopedic Oncologist, Seattle Cancer Care Alliance
CASE STUDY
-- 62 year old male with right posterior arm soft tissue mass
-Close approximation to radial nerve
-Close approximation to humerus
• Image guided needle biopsy- synovial sarcoma
• Neoadjuvant chemotherapy
– Pazopanib trial
• Neoadjuvant radiation therapy
– Planned positive margin on radial nerve and humerus
• No increased risk of local recurrence
• Preserve function
Excision
Negative margin
Innervated latissimus flap to restore function
Sarcoma: Multi-disciplinary Team
• Treatment decisions not made independently by one specialty
• Essential to have multidisciplinary discussion– Surgeon(s)
– Radiation oncologist
– Medical oncologist
– Radiologist
– Pathologist
All have input into management of every case
One modality may optimize management of another
SCCA: Multi-disciplinary Sarcoma Program
Medical Oncology
Orthopaedic Oncology
Radiation Oncology
General Surgery
Jones, RobinConrad, Ernest ‘Chappie’
Kane, Gabrielle
Mann, Gary
Loggers, Elizabeth
Davidson, Darin Kim, EdwardPillarisetty, Venu
Pollack, SethLindberg, Antoinette
Pathology Radiology PediatricsPlastic Surgery
Hoch, Ben Ha, AliceHawkins, Doug
Neligan, Peter
How to contact us• Scheduling Contact: Leslie Fischer
Telephone: 206.288.2018Fax: 206.288.6996Email: [email protected]; [email protected]
• Nursing Telephone: 206.288.2018Email: [email protected]
• Darin DavidsonTelephone: 206.543.3690Email: [email protected]
Soft Tissue Sarcoma
• Benign soft tissue masses much more common than malignant masses
–Approximately 100:1
• Red flags for STS vs benign mass
–Large (>5cm)
–Deep to fascia
• Age, presence of symptoms, duration not contributory
Clinical Presentation And Assessment
• Usually painless mass
–Pain suggestive of neural origin, rapid growth
• History- NF, sarcoma associated syndromes (Li-Fraumeni, Retinoblastoma)
• Key on physical exam
–Depth of lesion relative to fascia
Imaging
• MRI is preferred imaging modality
• Sarcoma suggested by signal intensity heterogeneity
– Imaging characteristics are not typical of particular type of soft tissue sarcoma
– Fluid signal may be present in setting of necrosis or hemorrhage
High grade soft tissue sarcoma with areas of hemorrhage and necrosis
Management
• Local and systemic staging
–MRI of affected area
–Biopsy
–CT chest
• Mainstay of treatment is surgical resection
• Adjuvants
–Radiation therapy
–Chemotherapy
• Aggressive or malignant appearing bone or soft tissue lesions
• Soft tissue mass- >5cm, deep to fascia or overlying bone or neurovascular structures• Except definitive imaging of benign mass (eg.
lipoma)• Unclear diagnosis in symptomatic patient• Solitary bone lesion in a patient with a history of
carcinoma• Even if fractured!!• Just need to confirm not sarcoma
Indications for Biopsy
Biopsy Principles
• An asymptomatic (latent) or symptomatic bone lesion (active) that appears entirely benign on imaging does not need a biopsy
• A soft tissue lesion that appears entirely benign on MRI (lipoma, hemangioma) does not need a biopsy
• When in doubt, it is safer to do a biopsy
Biopsy Principles
• Extensile incision – longitudinal in extremities• Tract needs to be excised
• Avoid developing planes• Use involved compartment• Do not expose neurovascular structures• Meticulous hemostasis• Release tourniquet prior to wound closure• If using drain, bring out in line with incision• For bone lesions, ok to biopsy soft tissue mass• Frozen section
Importance of the Biopsy
• Whatever is exposed to the tumor is potentially contaminated and must be excised at definitive treatment
• When biopsy principles aren’t followed
– Increased risk of• Wrong diagnosis
• Altered treatment
• Altered outcome
• Complications
• Local recurrence of STS
Mankin et al, 1996
Noria et al, 1996
Surgical Resection
• Goal is complete resection of tumor with ‘adequate’ margin
–Definition of adequate margin controversial
–Use of preoperative radiation can affect extent of margin required
•Marginal excision of STS- LR >30%
•Marginal excision of STS after neoadjuvant XRT- LR <10%
•Consideration for preservation of vital (major nerves, vessels, bone) structures to preserve function
Gerrand et al, JBJS-B 2001
Radiation Therapy
• Neoadjuvant XRT ‘sterilizes’ reactive zone surrounding the tumor
–Allows for closer margin (still complete resection with negative margin)
• Preserve critical structures and improve function
• Neoadjuvant XRT uses lower dose (50 Gy) compared to postop (66 Gy)
–Decreased fibrosis, edema (Davis et al, JCO 2002)
–Decreased risk of radiation induced fracture (Holt et al, JBJS-A 2005)
Overall survival comparing preoperative and postoperative XRT, indicating slightly higher overall survival
in the preoperative group.
O’Sullivan et al, Lancet, 2002
Radiation Therapy
• The downside to neoadjuvant XRT
–Higher risk of wound healing complications, infection
–RCT of neoadjuvant vs adjuvant XRT (O’Sullivan et al, Lancet 2002) comparing wound healing complications requiring return to OR
• Neoadjuvant XRT 35%
• Adjuvant XRT 17%
Radiation Therapy
• Decision between neoadjuvant and adjuvant is balance of risks
– Edema and fibrosis are not treatable and are disabling
– Radiation associated fracture can be difficult to treat
– Wound complications can be managed (may require prolonged treatment, multiple procedures)
Local Control
• Goal of local treatment is local control
• Traditional predictors of local recurrence
– Grade, size, depth
• Competing risk model demonstrates margin status at resection is the most important predictor of local control (Biau et al, 2012)
– Multi-modal local treatment
Chemotherapy
• Role of chemotherapy
– Role in metastatic disease
– Controversial for localized disease
• Meta-analyses have shown slight survival advantage with chemotherapy
Lancet , 1997
Meta-analysis of adjuvant chemotherapy in localized soft tissue sarcoma
Hazard ratio of survival for meta-analysis of adjuvant chemotherapy in localized soft tissue sarcoma
Pervaiz et al, Cancer 2008
Outcome
• Outcome best considered on basis of initial disease
–Localized disease
•Superficial, low grade ≈ 100% 5 year survival
•Deep, high grade ≈50% 5 year survival
–Metastatic disease at presentation (Ferguson et al, Cancer 2010)
•Pulmonary mets- 8% 5 year survival
•Lymph node mets- 59% 5 year survival
Soft Tissue Sarcoma Pitfalls
• Soft tissue sarcoma grow quickly and are painful
– Synovial sarcoma known for slow growth
• Well circumscribed, smooth border of mass = benign and infiltrative, irregular border = sarcoma
47 year old male with well circumscribed mass; biopsy proven synovial sarcoma
Fibromatosis
Summary
• Benign soft tissue masses are far more common than sarcoma, but beware
–Large mass
–Deep mass
• MRI is imaging modality of choice
• Biopsy principles essential
• Surgical resection is mainstay of treatment of localized soft tissue sarcoma
–XRT- consider advantages and disadvantages to preoperative vs postoperative
–Chemotherapy- slight survival advantage